scholarly journals Discovery of urine biomarkers for lupus nephritis via quantitative and comparative proteome analysis

2021 ◽  
Vol 11 (11) ◽  
Author(s):  
Oh Chan Kwon ◽  
Eun‐Ju Lee ◽  
Jeonghun Yeom ◽  
Seokchan Hong ◽  
Chang‐Keun Lee ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Proteome Analysis ◽  
Urine Biomarkers

scholarly journals Predicting decline of kidney function in lupus nephritis using urine biomarkers

Lupus ◽  
2016 ◽  
Vol 25 (9) ◽  
pp. 1012-1018 ◽  
Author(s):  
K M Abulaban ◽  
H Song ◽  
X Zhang ◽  
P L Kimmel ◽  
J W Kusek ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Kidney Function ◽  
Urine Biomarkers

scholarly journals Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults

2017 ◽  
Vol 44 (8) ◽  
pp. 1239-1248 ◽  
Author(s):  
Hermine I. Brunner ◽  
Michael R. Bennett ◽  
Gaurav Gulati ◽  
Khalid Abulaban ◽  
Marisa S. Klein-Gitelman ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Transforming Growth Factor ◽  
Kidney Biopsy ◽  
Characteristic Curve ◽  
Kidney Injury ◽  
Transforming Growth Factor Β ◽  
Response To Therapy ◽  
Spot Urine ◽  
Urine Biomarkers

Objective.To delineate urine biomarkers that forecast response to therapy of lupus nephritis (LN).Methods.Starting from the time of kidney biopsy, patients with childhood-onset systemic lupus erythematosus who were diagnosed with LN were studied serially. Levels of 15 biomarkers were measured in random spot urine samples, including adiponectin, α-1-acid glycoprotein (AGP), ceruloplasmin, hemopexin, hepcidin, kidney injury molecule 1, monocyte chemotactic protein-1, lipocalin-like prostaglandin D synthase (LPGDS), transforming growth factor-β (TGF-β), transferrin, and vitamin D binding protein (VDBP).Results.Among 87 patients (mean age 15.6 yrs) with LN, there were 37 treatment responders and 50 nonresponders based on the American College of Rheumatology criteria. At the time of kidney biopsy, levels of TGF-β (p < 0.0001) and ceruloplasmin (p = 0.006) were significantly lower among responders than nonresponders; less pronounced differences were present for AGP, hepcidin, LPGDS, transferrin, and VDBP (all p < 0.05). By Month 3, responders experienced marked decreases of adiponectin, AGP, transferrin, and VDBP (all p < 0.01) and mean levels of these biomarkers were all outstanding (area under the receiver-operating characteristic curve ≥ 0.9) for discriminating responders from nonresponders. Patient demographics and extrarenal disease did not influence differences in biomarker levels between response groups.Conclusion.Low urine levels of TGF-β and ceruloplasmin at baseline and marked reduction of AGP, LPGDS, transferrin, or VDBP and combinations of other select biomarkers by Month 3 are outstanding predictors for achieving remission of LN. If confirmed, these results can be used to help personalize LN therapy.

A78: Urine Biomarkers Role in Predicting the Future Development of Renal Functional Loss With Lupus Nephritis in Children and Adults

2014 ◽  
Vol 66 ◽  
pp. S111-S111 ◽  
Author(s):  
Khalid Abulaban ◽  
Hermine Brunner ◽  
Shannen L. Nelson ◽  
Michael Bennett ◽  
Jun Ying ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Future Development ◽  
Functional Loss ◽  
Urine Biomarkers ◽  
The Future

Urine biomarkers for monitoring juvenile lupus nephritis: a prospective longitudinal study

2013 ◽  
Vol 29 (3) ◽  
pp. 397-405 ◽  
Author(s):  
Louise Watson ◽  
Kjell Tullus ◽  
Clarissa Pilkington ◽  
Christine Chesters ◽  
Stephen D. Marks ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Lupus Nephritis ◽  
Prospective Longitudinal Study ◽  
Urine Biomarkers ◽  
Prospective Longitudinal

scholarly journals Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review

2021 ◽  
pp. 1-13
Author(s):  
Massimo Radin ◽  
Paolo Miraglia ◽  
Alice Barinotti ◽  
Roberta Fenoglio ◽  
Dario Roccatello ◽  
...  
Keyword(s):  
Systematic Review ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Gold Standard ◽  
Daily Practice ◽  
Cross Sectional ◽  
Urine Biomarkers ◽  
Diagnostic Values ◽  
Serological Biomarkers ◽  
Serum And Urine

<b><i>Introduction:</i></b> While renal biopsy remains the gold standard for diagnosing lupus nephritis (LN), the prognostic and diagnostic role of non-invasive biomarkers for LN is currently debated. <b><i>Methods:</i></b> Available studies published in last 5 years (2015–2020) assessing the diagnostic and prognostic value of urinary and/or serological biomarkers in subjects with LN were analyzed in this systematic review. <b><i>Results:</i></b> Eighty-five studies were included (comprehending 13,496 patients with systemic lupus erythematosus [SLE], 8,872 LN, 487 pediatric LN, 3,977 SLE but no LN, 160 pediatric SLE but no LN and 7,679 controls). Most of the studies were cross-sectional (62; 73%), while 14 (17%) were prospective. In sixty studies (71%), the diagnosis of LN was biopsy-confirmed. Forty-four out of 85 (52%) investigated only serological biomarkers, 29 studies (34%) tested their population only with urinary biomarkers, and 12 (14%) investigated the presence of both. Outcome measures to assess the clinical utility of the analyzed biomarkers were heterogeneous, including up to 21 different activity scores, with the SLEDAI (in 60%) being the most used. Despite some heterogeneity, promising results have been shown for biomarkers such as urinary monocyte chemoattractant protein, urinary adiponectin, and urinary vascular cell adhesion protein 1. <b><i>Discussion/Conclusion:</i></b> While serum and urine biomarkers have the potential to improve diagnostic and prognostic pathways in patients with LN, the vast heterogeneity across studies severely limits their applicability in current clinical practice. With the kidney biopsy still representing the gold standard, future efforts should focus on harmonizing study inclusion criteria and outcomes, particularly in clinical trials, in order to improve comparability and facilitate the implementations of available biomarkers into the daily practice.

Sign in / Sign up

Export Citation Format

Share Document